US/UK/Canada

Share

Contacts

  • Maria Nilsson

    EVP Communication & Public Relations


    +46 10 335 4866
    +46 734 244 515
  • Arjo AB
    Hans Michelsensgatan 10 211 20 Malmö SWEDEN
    +46 10 335 4500
    http://www.arjo.com
    • Pick a time period -
    Tags ( Active)

    Arjo receives the Allbright Prize 2024

    The medical technology company Arjo has been awarded the 2024 Allbright Prize for purposeful and long-term work with equality, diversity and inclusion. The prize was awarded at a ceremony in Stockholm today. Allbright, a non-partisan and non-profit foundation that works for equality and diversity in management teams, writes in its motivation: "Arjo is a shining example of how conscious and systematic work for equality and diversity can create a more inclusive workplace and at the same time contribute to business success." "With a genuine commitment, Arjo has also identified structures

    Arjo’s interim report January-September 2024

    ”Growth continued in the quarter with a strengthened order book and improved gross margin. Our performance was, however, held back by weaker demand in Europe. We are now accelerating initiatives to improve both short- and long-term profitability. We enter the final quarter of the year with high activity level and expect to reach our ambition of 3-5% organic growth for the full-year,” says Joacim Lindoff, President and CEO of Arjo. July-September 2024 in brief · Net sales amounted to SEK 2,734 M (2,777). Net sales grew organically by 1.5%. · The gross margin increased to 42.0%

    Arjo’s interim report January-March 2024

    ”We start the year with growth and improved profitability. Rental and service develop well globally and the positive trend in the US continues, with a gradual improvement of the market situation. Overall, a solid start to the year and I look forward to continue the work together with the team to strengthen Arjo’s positions in 2024,” says Joacim Lindoff, President and CEO of Arjo. January-March 2024 in brief · Net sales increased to SEK 2,759 M (2,638).Net sales grew organically by 4.3%. · Adjusted EBITDA increased 5.7% to SEK 502 M (475). · Adjusted operating profit

    Arjo’s interim report January-June 2023

    ”The recovery following a turbulent 2022 continues and we grew 5% organically with improved profitability and strong cash flow. Demand was healthy in many markets and despite continuing challenging market conditions in the US, we expect to deliver organic growth for the full-year within our target interval of 3–5%,” says Joacim Lindoff, President and CEO of Arjo.  April-June 2023 in brief · Net sales increased to SEK 2,686 M (2,404).Net sales grew organically by 5.0%. · Adjusted EBITDA rose to SEK 490 M (430). · Adjusted operating profit increased to SEK 206 M (165). ·

    Arjo’s interim report January-March 2023

    ”The Group grew organically by 4.3%, giving us a stable start to the year. Demand for Arjo’s products and solutions was high, and despite a volatile market we remain confident that we will reach the target of 3–5% organic growth for the full-year,” says Joacim Lindoff, President and CEO of Arjo. January-March 2023 in brief · Net sales increased to SEK 2,638 M (2,370).Net sales grew organically by 4.3%. · Adjusted EBITDA amounted to SEK 474 M (490). · Adjusted operating profit amounted to SEK 196 M (237). · Profit after financial items amounted to SEK 126 M (218). ·

    Arjo’s year-end report January-December 2022

    ”We close a year in which growth was primarily held back by lower critical care rental volumes in the US compared with 2021. Adjusted for this the Group grew organically by approximately 3% in 2022, which demonstrates the strength of our underlying business. During the fourth quarter, growth continued across all major markets outside the US, and we report an adjusted EBITDA-result of SEK 500 M. In addition, reduced inventory levels contribute to a cash conversion above our target,” says Joacim Lindoff, President and CEO of Arjo. “We manage the short-term challenges in our environment and

    Arjo announces date for 2022 year-end report and conference call

    Arjo will issue its year-end report for 2022 on Wednesday January 25 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO. Fund managers, analysts and media are invited to participate in a conference call and presentation of the report via the following link: https://ir.financialhearings.com/arjo-q4-report-2022  Those who wish to ask questions verbally via the teleconference will need to register via the link below. A phone number and a conference ID will be provided after registration in order to access the

    Arjo interim report January-June 2022

    “Market demand remains healthy and the order book for capital equipment continues to be significantly above last year’s levels. Performance in the quarter is held back by short-term challenges due to postponed sales in patient handling, significantly lower critical care rental volumes in the US compared with last year, and continued supply chain disruptions,” says Joacim Lindoff, President & CEO of Arjo. “We have a continued positive momentum within many areas and our underlying business continues to develop well. We estimate that growth will gradually increase in the year’s final two

    Arjo interim report January-March 2022

    ”Demand for our products and solutions remains very high. The Group grew organically by 1.4%, supported by a strong order intake and an order book for capital equipment which is now significantly higher than at the end of the corresponding period last year. The global challenges within supply chain remain, and the organization continues to manage the situation with sharp focus,” says Joacim Lindoff, President & CEO. “We have a high activity level that is now approaching the level we saw before the pandemic, and we continue to implement our strategy with full force. A brand new generation

    Arjo publishes year-end report January-December 2021

    ”We deliver our strongest year to date and grow organically by 3.5%. The entire organization has done a fantastic job in supporting healthcare providers while managing the challenges related to the global supply constraints in a very good way. This enables us to improve both our profitability and financial position, and I am happy to be able to propose a dividend of 1.15 SEK per share – a 35% increase compared to last year,” says Joacim Lindoff, President & CEO of Arjo. ”We enter into 2022 with high activity level and a strong order book. We have proven that we are capable of adapting to

    Arjo announces date of 2021 year-end report and conference call

    Arjo will issue its year-end report for 2021 on Thursday February 3 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO. We invite fund managers, analysts and the media to participate in the conference call. Please see details below to join the conference.  Sweden: +46 8 566 427 03USA: +1 646 722 4903UK: +44 333 300 9032 During the telephone conference, a presentation will be held. To access the presentation, please use this link: https://tv.streamfabriken.com/arjo-q4-2021 Alternatively, use the following

    Arjo interim report January-September 2021

    ”Our profitable growth continues in the third quarter with net sales growing over 5% organically and a nearly 35% increase in adjusted EBIT. We have also reached several important milestones in the commercialization of the new SEM Scanner in the quarter, including a contract with one of the largest GPOs in the US,” says Joacim Lindoff, President & CEO. “We enter the year’s final quarter with a high activity level and well-filled order books, and look forward to delivering a strong finish to 2021,” adds Joacim Lindoff. July-September 2021 in brief · Net sales increased to SEK 2,247 M

    Arjo announces date of 2021 Q3 report and conference call

    Arjo will issue its Q3 report for 2021 on Thursday October 28 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO. We invite fund managers, analysts and the media to participate in the conference call. Please see details below to join the conference.  Sweden: +46 8 505 583 52USA: +1 646 722 4903UK: +44 333 300 9032 During the telephone conference, a presentation will be held. To access the presentation, please use this link: https://tv.streamfabriken.com/arjo-q3-2021 Alternatively, use the following link

    Arjo receives 510(k) clearance from US FDA for WoundExpress

    Arjo has received 510(k) clearance from the US Food and Drug Administration (FDA) for WoundExpress, an intermittent pneumatic compression (IPC) solution for accelerating healing of venous leg ulcers. The FDA clearance follows several recent studies showing that WoundExpress can significantly improve lower leg wound management. “This is an important milestone for us and we see great potential in now bringing this innovative therapy to the US market as well”, says Joacim Lindoff, President & CEO of Arjo. “Venous leg ulcers are a rapidly growing and costly problem for healthcare, with

    Arjo interim report January-June 2021

    ”We close another strong quarter and grow organically by 4,0%, supported by a solid order intake. We successfully navigate the Covid-19 challenges and see a continued recovery within profitable categories like patient handling, service and DVT. Our profitability continues to improve and we report an adjusted EBITDA-margin exceeding 23% for the first time,” says Joacim Lindoff, President & CEO. “The implementation of our long-term strategy continues with full force, at the same time as we are delivering on our short-term targets. Our newly launched SEM scanner is generating high interest

    Arjo interim report January-March 2021

    “We close a strong first quarter where we continue to successfully navigate the Covid-19 challenges. We grow organically by 4,1%, with a strong profitability development where we report our highest gross margin for a single quarter to date, and our adjusted operating profit increases by 45% in comparable currencies. Our rental business grows by double-digit numbers with a solid performance in core rental both in the US and Europe. At the end of the quarter we also saw an accelerated activity level in capital sales, especially within the Patient handling category which grows 15% in the

    Arjo Annual Report 2020 – Mobility drives improved outcomes in healthcare

    Today Arjo publishes the Annual Report for 2020. A success factor during the year was that Arjo navigated the short-term challenges in connection with the pandemic while capitalizing on new business opportunities and investing in the future. In 2020, Arjo also presented a new strategy for 2030 as well as a new sustainability framework. “We put an exceptional year behind us, where we have adapted the business to the current circumstances and supported healthcare in a challenging time. At the same time, we exceeded the targets that we set at the beginning of the year. Three years have

    Arjo publishes year-end report January-December 2020

    ”We put a very strong quarter and year behind us where we have adapted the business to the current circumstances, and supported healthcare in a challenging period. At the same time, we have exceeded all of the targets that we set at the beginning of the year. The Group grows organically by more than 4% in the fourth quarter with our adjusted operating profit increasing more than 20% in comparable currencies. A record strong cash flow further strengthens our financial position, and allows us to propose an increased dividend of more than 30% to our shareholders compared with last year,” says

    Arjo announces date of 2020 year-end report and conference call

    Arjo will issue its year-end report for 2020 on Wednesday February 3 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO. We invite fund managers, analysts and the media to participate in the conference call. Please see details below to join the conference.  Swedish dial-in number: +46 8 566 426 93          USA: +1 833 823 0587UK: +44 3333 009 268 During the telephone conference, a presentation will be held. To access the presentation, please use this link: https://tv.streamfabriken.com/arjo-q4-2020

    Arjo acquires AirPal – a US company focused on patient transfers

    Arjo today announces the acquisition of AirPal, a privately owned US-based company specializing in Air-Assisted Lateral Patient Transfer solutions. The deal will strengthen Arjo’s Patient Handling portfolio and is expected to have a positive impact on earnings per share from 2022 and onwards.“By adding AirPal’s products to our sales force we are able to fast-track our position within Air-Assisted Lateral Transfer solutions in the important US market. This adds further growth potential to our Patient Handling business where we can now offer a more complete solution to our customers. With

    Arjo presents updated strategy for continued profitable growth

    Arjo’s updated strategy and new financial targets for 2021-2023 will be presented today at the Group’s Capital Markets Day. With the new strategy, Arjo is taking an important step in offering outcome-based solutions for healthcare, while focusing on enhancing efficiency. The financial targets include annual organic growth of 3-5% combined with an adjusted EBITDA margin of approximately 23% toward the end of the period, and annual cash conversion of more than 80%. “Since our listing three years ago, we have built a solid foundation and taken Arjo back to profitable growth. Now we are

    Arjo interim report January-september 2020

    ”We add a very strong quarter to the books. We continue to deliver profitable growth and grow organically by 5.8% in the quarter, while increasing our operating profit by 67%,” says Joacim Lindoff, President and CEO. “The challenges associated with Covid-19 continues and we are handling the situation here and now while investing in our long-term agenda. We enter the fourth quarter with a good momentum and look forward to finish the year on a positive note,” adds Joacim Lindoff. July-september 2020 in brief · Net sales amounted to SEK 2,143 M (2,154).Net sales grew organically by 5.

    Arjo announces date of 2020 Q3 report and conference call

    Arjo will issue its Q3 report for 2020 on Wednesday October 28 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO. We invite fund managers, analysts and the media to participate in the conference call. Please see details below to join the conference.  Swedish dial-in number: +46 8 519 993 83USA: +1 833 526 8383UK: +44 3333 009 266 During the telephone conference, a presentation will be held. To access the presentation, please use this link: https://tv.streamfabriken.com/arjo-q3-2020 Alternatively, use

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media